Aridis expands Phase 2a trial of AR-301 into the US
9 July 2015 | By Victoria White
The US Food and Drug Administration (FDA) has accepted Aridis Pharmaceuticals’ Investigational New Drug (IND) application for AR-301 (Salvecin)...
List view / Grid view
News
Progesterone could help treat breast cancer
9 July 2015 | By Victoria White
Around half of all breast cancer patients could one day benefit from having the cheap and widely-available hormone progesterone added to their treatment...
Phase 2b findings demonstrate efficacy of guselkumab in treatment of moderate to severe plaque psoriasis
9 July 2015 | By Victoria White
A trial of has shown up to 86% of patients with psoriasis receiving guselkumab achieved a PGA score of cleared psoriasis or minimal psoriasis at week 16...
Sanofi extends collaboration with Medicines for Malaria Venture
8 July 2015 | By Victoria White
Sanofi is to extend its collaboration with Medicines for Malaria Venture (MMV) to jointly develop a new single, fixed-dose combination therapy for malaria...
Arrowhead receives regulatory clearance for ARC-AAT Phase 1 study in the UK and New Zealand
8 July 2015 | By Victoria White
Arrowhead Research Corporation has received regulatory permission in the UK and New Zealand to proceed with Part B of its Phase 1 study of ARC-AAT...
Lilly’s NSCLC drug necitumumab shows risk of blood clots
8 July 2015 | By Victoria White
Lilly’s NSCLC drug, necitumumab, has raised concerns with the FDA after trial data suggested that the drug might increase the likelihood of fatal clots...
AXON Neuroscience’s vaccine designed to halt Alzheimer’s finishes Phase 1 clinical trial
8 July 2015 | By Victoria White
AXON Neuronscience's vaccine intended to be a disease modifying drug for Alzheimer’s disease patients has passed a Phase 1 safety trial...
FDA approves heart failure treatment Entresto
8 July 2015 | By Victoria White
The US Food and Drug Administration (FDA) has approved Novartis' Entresto (sacubitril/valsartan) tablets for the treatment of heart failure with reduced ejection fraction.
DSMB recommends continuation of Genticel’s Phase 2 clinical trial of GTL001
8 July 2015 | By Victoria White
Genticel has announced that the independent Data Safety Monitoring Board recommends the continuation, per protocol, of its Phase 2 clinical trial of GTL001...
First-in-class epilepsy treatment Fycompa launches in the UK
8 July 2015 | By Victoria White
Eisai’s Fycompa (perampanel), a once-daily epilepsy treatment that inhibits AMPA receptors, launches in the United Kingdom today...
Serious adverse events rare in healthy volunteers participating in Phase I trials
7 July 2015 | By Victoria White
A new study has found that less than 1% of 11,000 healthy volunteers who participated in 394 Phase I trials for new drugs experienced serious complications...
Celtaxsys gains US clearance for Phase 2 trial of acebilustat in patients with cystic fibrosis
7 July 2015 | By
Celtaxsys has gained clearance from the US FDA to begin a Phase 2 clinical trial of acebilustat in adult patients with cystic fibrosis (CF) in the US...
Pfizer begins Phase 2b study of S. aureus vaccine in adults undergoing elective spinal fusion surgery
7 July 2015 | By Victoria White
The first patients have been enrolled in a Phase 2b clinical trial of Pfizer’s S. aureus vaccine in adults undergoing elective spinal fusion surgery...
Allergan to acquire exclusive worldwide rights to Merck’s CGRP migraine development programme
7 July 2015 | By Victoria White
Allergan is to acquire exclusive worldwide rights to Merck's CGRP receptor antagonists, which are being developed for the treatment of migraine...
Over-the-counter antacid lansoprazole could be an effective anti-tuberculosis drug
7 July 2015 | By Victoria White
Testing thousands of approved drugs, EPFL scientists have found that an over-the-counter antacid, lansoprazole, may be an effective anti-tuberculosis drug...
